Orbimed Advisors LLC Mirati Therapeutics, Inc. Transaction History

Orbimed Advisors LLC

$4.44 Billion
Q1 2024

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$27.8 - $45.35 $29.1 Million - $47.4 Million	1,045,400 Added 114.42%	1,959,050 $85.3 Million
Q1 2023 May 15, 2023	SELL	$36.54 - $54.26 $13.5 Million - $20.1 Million	-370,042 Reduced 28.83%	913,650 $34 Million
Q4 2022 Feb 14, 2023	SELL	$41.27 - $98.62 $5.58 Million - $13.3 Million	-135,200 Reduced 9.53%	1,283,692 $58.2 Million
Q3 2022 Nov 14, 2022	BUY	$59.5 - $86.7 $19.5 Million - $28.5 Million	328,492 Added 30.13%	1,418,892 $99.1 Million
Q2 2022 Aug 15, 2022	SELL	$39.16 - $88.71 $21.2 Million - $47.9 Million	-540,100 Reduced 33.12%	1,090,400 $73.2 Million

Q1 2022 May 16, 2022	BUY	$75.82 - $150.97 $15.5 Million - $30.8 Million	204,100 Added 14.31%	1,630,500 $134 Million
Q4 2021 Feb 14, 2022	BUY	$132.01 - $190.29 $7.02 Million - $10.1 Million	53,200 Added 3.87%	1,426,400 $209 Million
Q3 2021 Nov 15, 2021	BUY	$132.13 - $177.45 $14.4 Million - $19.3 Million	109,000 Added 8.62%	1,373,200 $243 Million
Q2 2021 Aug 16, 2021	BUY	$144.0 - $179.73 $6.19 Million - $7.73 Million	43,000 Added 3.52%	1,264,200 $204 Million
Q1 2021 May 17, 2021	BUY	$158.92 - $221.61 $12.1 Million - $16.8 Million	75,900 Added 6.63%	1,221,200 $209 Million
Q4 2020 Feb 16, 2021	SELL	$162.05 - $240.27 $27.8 Million - $41.3 Million	-171,700 Reduced 13.04%	1,145,300 $252 Million
Q3 2020 Nov 16, 2020	SELL	$113.26 - $167.27 $804,146 - $1.19 Million	-7,100 Reduced 0.54%	1,317,000 $219 Million
Q2 2020 Aug 14, 2020	SELL	$72.01 - $120.39 $7.14 Million - $11.9 Million	-99,200 Reduced 6.97%	1,324,100 $151 Million
Q1 2020 May 15, 2020	BUY	$69.78 - $116.21 $5.77 Million - $9.61 Million	82,700 Added 6.17%	1,423,300 $109 Million
Q4 2019 Feb 14, 2020	BUY	$70.76 - $128.86 $57 Million - $104 Million	805,457 Added 150.51%	1,340,600 $173 Million
Q3 2019 Nov 14, 2019	BUY	$77.91 - $109.6 $41.7 Million - $58.7 Million	535,143 New	535,143 $41.7 Million

Others Institutions Holding MRTX

# of Institutions

Shares Held

3.57M

Call Options Held

Put Options Held

36.6K

View Full List

About Mirati Therapeutics, Inc.

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

More about MRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Orbimed Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Orbimed Advisors LLC with notifications on news.

Account